Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7xN2lKSzVyPUCuNFA3PjlizszN NWnqTVBuW0GQR1XS
MV-4-11 M2foT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEG1PFYh|ryP NX;kZmxpW0GQR1XS
NKM-1 NI[1WVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEG2PVkh|ryP MVTTRW5ITVJ?
ML-2 NVv3U5dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEG5PFMh|ryP MX\TRW5ITVJ?
BV-173 NFvRc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XOOmlEPTB;MD6wNlMyPCEQvF2= NHTzbotUSU6JRWK=
RS4-11 NFrU[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XUWmlEPTB;MD6wNlU5PyEQvF2= NF7SWVVUSU6JRWK=
HL-60 NE[ycldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfrTWM2OD1yLkCyPVA5KM7:TR?= NGf2TIFUSU6JRWK=
KY821 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEK5O|Uh|ryP MUPTRW5ITVJ?
ECC10 M4DYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfMbXdKSzVyPUCuNFM4QTJizszN MoXpV2FPT0WU
NCI-H720 NFznfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyRWpJUUN3ME2wMlA1ODFzIN88US=> NVzUXFFYW0GQR1XS
QIMR-WIL NX7zemFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPyTWM2OD1yLkC0Nlg4KM7:TR?= MULTRW5ITVJ?
KG-1 NWLUSW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3NpNKSzVyPUCuNFQ1QDZizszN M2XSeHNCVkeHUh?=
TGW NIG1TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;0UVJSUUN3ME2wMlA1PjN|IN88US=> MXzTRW5ITVJ?
ATN-1 NF3MNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMES3N|Mh|ryP M3PGS3NCVkeHUh?=
RH-18 NX\DcVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXIXHJKSzVyPUCuNFYxPDhizszN MnmyV2FPT0WU
EW-18 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwME[4OFEh|ryP NYriO44yW0GQR1XS
NB17 M2\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGTGFKSzVyPUCuNFcyOjRizszN NIXkbItUSU6JRWK=
SK-NEP-1 NHnHcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP2b3lKSzVyPUCuNFczOTNizszN NXK4Xm5zW0GQR1XS
P12-ICHIKAWA NETQZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzdmlEPTB;MD6wO|c4QCEQvF2= MkHTV2FPT0WU
KARPAS-45 NYT0bpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\JfFlKSzVyPUCuNFc5OTVizszN M4\0S3NCVkeHUh?=
EW-3 NG\QSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS5[2RVUUN3ME2wMlA5ODV|IN88US=> MV7TRW5ITVJ?
NB13 M4nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M160fWlEPTB;MD6wPFIxOyEQvF2= NWPXe3NyW0GQR1XS
NCI-H209 NET3VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEi3NFQh|ryP MonsV2FPT0WU
NCI-H1092 NEHhSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0XmpKSzVyPUCuNVAzPzVizszN MWLTRW5ITVJ?
NH-12 NF\tZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XDcWlEPTB;MD6xNFc1PCEQvF2= MmPGV2FPT0WU
697 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LB[mlEPTB;MD6xNFg{QSEQvF2= NG[3OFlUSU6JRWK=
KE-37 NWLFXJhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nCOmlEPTB;MD6xNVM4KM7:TR?= NFL3[o1USU6JRWK=
MOLT-4 NUP4VGRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrsOIhKSzVyPUCuNVUyPjlizszN M{S3enNCVkeHUh?=
CHP-134 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jYeGlEPTB;MD6xOlMxPiEQvF2= MnPvV2FPT0WU
D-283MED NYnCfnl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:2UGlEPTB;MD6xO|Y5PiEQvF2= MlTkV2FPT0WU
LU-135 M3TjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0ZpE4UUN3ME2wMlE5PTV{IN88US=> NGPXZZJUSU6JRWK=
LU-134-A NV2wTJk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUi2O|Eh|ryP M{nXTXNCVkeHUh?=
EM-2 NF\kRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD0TWM2OD1yLkG5PVE5KM7:TR?= NFTSV4lUSU6JRWK=
LU-139 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPGR5dKSzVyPUCuNlA1QThizszN NWT2Z|Q2W0GQR1XS
ALL-PO M{mycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLmXllKSzVyPUCuNlE6QDhizszN NVv5SmJsW0GQR1XS
NB12 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TKXmlEPTB;MD6yN|EyPSEQvF2= MnzDV2FPT0WU
KP-N-YN M1[5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIOo5RUUN3ME2wMlI{PTd|IN88US=> NYL5RXlHW0GQR1XS
BEN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzKXGU2UUN3ME2wMlI{QTZ6IN88US=> NH\RTY9USU6JRWK=
HCC1569 M1j5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX36cmRKUUN3ME2wMlI2OTB4IN88US=> MUHTRW5ITVJ?
HuO9 NEHlOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1yLkK2O|E2KM7:TR?= MnTnV2FPT0WU
WM-115 NX3mdYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnmdmZGUUN3ME2wMlI4PzN6IN88US=> NUDUNlQ4W0GQR1XS
CCRF-CEM NF\aVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zQV2lEPTB;MD6zN|UzQSEQvF2= NFPhellUSU6JRWK=
IST-SL1 NGC2ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{WzOFMh|ryP MYfTRW5ITVJ?
BE-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3OWVyUUN3ME2wMlM3PDV7IN88US=> Mn7lV2FPT0WU
COR-L88 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X3NGlEPTB;MD6zOlU1KM7:TR?= MVvTRW5ITVJ?
DOHH-2 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNEGwNlMh|ryP M3LrNXNCVkeHUh?=
A704 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNEK2O{DPxE1? NXnWdVh3W0GQR1XS
KNS-81-FD NF22fnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTsTWM2OD1yLkS0NFE4KM7:TR?= NFXXd21USU6JRWK=
RPMI-8226 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjjTWM2OD1yLkS1OlUzKM7:TR?= NFvBXGJUSU6JRWK=
TGBC24TKB NHvKbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTsTWM2OD1yLkS1O|c5KM7:TR?= M2XKWHNCVkeHUh?=
NCI-H1304 M2q1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHIRolKSzVyPUCuOFYyPTdizszN MW\TRW5ITVJ?
MOLT-13 NV2zRXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\TdWlEPTB;MD60OlYyOyEQvF2= M2fScXNCVkeHUh?=
EW-22 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNE[2O|Eh|ryP NYT2[5F[W0GQR1XS
MS-1 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC0WpNTUUN3ME2wMlQ3QTN|IN88US=> MU\TRW5ITVJ?
RMG-I MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfGRplTUUN3ME2wMlQ6PDZ2IN88US=> NVjD[pR7W0GQR1XS
NTERA-S-cl-D1 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf4SHlkUUN3ME2wMlUxODF7IN88US=> M1zIXHNCVkeHUh?=
NCI-H1048 M4C3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT2TWM2OD1yLkWwPVU{KM7:TR?= M{jIU3NCVkeHUh?=
SW1417 M4jwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{KxTWlEPTB;MD61OVQ{QCEQvF2= MXPTRW5ITVJ?
DB NV25c4ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj2TWM2OD1yLkW3NFgh|ryP MlTyV2FPT0WU
MEG-01 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNUizNkDPxE1? M1LucnNCVkeHUh?=
EW-13 NE\lPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJPJdKSzVyPUCuOVg{PDFizszN MkXSV2FPT0WU
LAMA-84 NFO3SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DlNWlEPTB;MD61PVIxPyEQvF2= NWPQWFNxW0GQR1XS
J-RT3-T3-5 M1qxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfONldkUUN3ME2wMlYxQDB6IN88US=> MknNV2FPT0WU
MOLT-16 M4TVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjYTZN1UUN3ME2wMlY2OjZ2IN88US=> M1K2dXNCVkeHUh?=
DU-4475 NHrFNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLEOW9OUUN3ME2wMlY2PDJ5IN88US=> NVfNW|hmW0GQR1XS
HAL-01 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fHW2lEPTB;MD63NlU1QSEQvF2= MlTvV2FPT0WU
RD M3fGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDKcWR7UUN3ME2wMlc2QDl7IN88US=> NYHTT3U1W0GQR1XS
OAW-28 Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwN{izO{DPxE1? NV73SnpyW0GQR1XS
HCC38 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TyU2lEPTB;MD64NFE6KM7:TR?= M4LDZnNCVkeHUh?=
NMC-G1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjLXHdKSzVyPUCuPFEyOjFizszN NV7VPFgzW0GQR1XS
EW-16 NVXZfWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLrTWM2OD1yLkixN|I5KM7:TR?= M3;OZXNCVkeHUh?=
DU-145 NHTYU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwOEm5NlMh|ryP MXrTRW5ITVJ?
HPAF-II NUHrNIpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjPN|BKSzVyPUCuPVI3OjhizszN M37GeXNCVkeHUh?=
A427 M3HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTjfW1uUUN3ME2wMlk{ODJ{IN88US=> NH;lUGxUSU6JRWK=
PA-1 M1z2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwOUW2OFIh|ryP Mmn0V2FPT0WU
OAW-42 NWTHUY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGwT2VKSzVyPUCuPVYyPDZizszN MmLjV2FPT0WU
L-428 NG\WSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j6R2lEPTB;MT6wNVI2KM7:TR?= NVXnfY9LW0GQR1XS
COLO-824 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYTWM2OD1zLkCxO|A5KM7:TR?= NGnGcYhUSU6JRWK=
P30-OHK MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzvTWM2OD1zLkC0Olg5KM7:TR?= MVvTRW5ITVJ?
NCI-H2170 MnPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwME[yN{DPxE1? NGL0W2FUSU6JRWK=
HCC2998 M{\lSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXKOIZKSzVyPUGuNFcyOzVizszN NEHydY1USU6JRWK=
NB14 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMUO3OFgh|ryP NI\EXGhUSU6JRWK=
TGBC1TKB NXu4[WZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfndo5KSzVyPUGuNVQyPTJizszN MkPXV2FPT0WU
KP-N-YS M4\RW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMU[yN|Yh|ryP NXO1TYtEW0GQR1XS
CAL-120 M4HNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPSO49KSzVyPUGuNVY1OjlizszN M17SRnNCVkeHUh?=
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn0TWM2OD1zLkG5NFU{KM7:TR?= M{P0Z3NCVkeHUh?=
C32 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXCeVF{UUN3ME2xMlE6ODh6IN88US=> MV7TRW5ITVJ?
HCC2157 M{fmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml65TWM2OD1zLkG5OFk1KM7:TR?= Ml;oV2FPT0WU
COLO-792 NXLPcpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPsRng2UUN3ME2xMlIxODdzIN88US=> NFqwRXRUSU6JRWK=
ES7 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TIfmlEPTB;MT6yO|k2OSEQvF2= MnTtV2FPT0WU
HEL NYrxN4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrUSG5OUUN3ME2xMlMyODJ7IN88US=> NYHjeGIyW0GQR1XS
ES4 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\2OGlEPTB;MT6zOFk6QCEQvF2= NXHCWWlWW0GQR1XS
NCI-SNU-1 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor1TWM2OD1zLkO2OVU2KM7:TR?= NUHTb49KW0GQR1XS
MDA-MB-415 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLkTWM2OD1zLkO4PFUh|ryP M1TBN3NCVkeHUh?=
NCI-H2342 NHuwPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrBTWM2OD1zLkSwNlY6KM7:TR?= NWX3PI8xW0GQR1XS
NB69 M2fsRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfYTWM2OD1zLkS2NlcyKM7:TR?= MV;TRW5ITVJ?
D-247MG M1XkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TDVGlEPTB;MT61NVEzOiEQvF2= NHrwVYxUSU6JRWK=
SCC-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jicGlEPTB;MT61PVg5PyEQvF2= MYnTRW5ITVJ?
HuH-7 M3TYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PsfWlEPTB;MT62O|I6OyEQvF2= MUnTRW5ITVJ?
A388 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTvOWtxUUN3ME2xMlY5PzJ2IN88US=> M4XNcnNCVkeHUh?=
Calu-3 NFf1WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwN{C2PVch|ryP M1\KRXNCVkeHUh?=
NCI-H1648 M3XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwN{G0NVgh|ryP MXTTRW5ITVJ?
NCI-H2052 NVzaOndyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[zeWpKSzVyPUGuO|IzODFizszN MkTnV2FPT0WU
Ramos-2G6-4C10 NEj6[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XwNGlEPTB;MT63N|Y2PiEQvF2= M{P5OnNCVkeHUh?=
DEL NX3JRYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD1zLke0OlkzKM7:TR?= M2TTVXNCVkeHUh?=
SNU-423 NHXpepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIriNo5KSzVyPUGuO|gyPTdizszN NV6zZmttW0GQR1XS
COR-L23 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzGOZVCUUN3ME2xMlc6QDd2IN88US=> NGTvR|RUSU6JRWK=
OMC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS4T5RUUUN3ME2xMlg3ODF4IN88US=> NX3yXnJWW0GQR1XS
EW-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYOlBKSzVyPUGuPVU3PTdizszN Mn:1V2FPT0WU
HSC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwOU[zOlUh|ryP M{npeXNCVkeHUh?=
MLMA M2TFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhc3NnUUN3ME2xMlk3Pjd5IN88US=> NH\IT5RUSU6JRWK=
RCM-1 NWL2R2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M136bGlEPTB;Mj6wNFM6QSEQvF2= M1;3cHNCVkeHUh?=
MFE-280 NYDVOlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1{LkCyPFQ5KM7:TR?= MUfTRW5ITVJ?
ES8 NV21Noh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwMkW0O|Eh|ryP MX\TRW5ITVJ?
TE-11 NIXu[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMkm0O|Mh|ryP NIT0dHVUSU6JRWK=
HuO-3N1 NX;mV5VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LBUWlEPTB;Mj60PFc5KM7:TR?= NFWzVHNUSU6JRWK=
MHH-NB-11 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwNUGxOVgh|ryP M3jvcnNCVkeHUh?=
TGBC11TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJwNUe2PFEh|ryP NH7CTmVUSU6JRWK=
HOP-92 NFHxSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfoPWdLUUN3ME2yMlU5PzR|IN88US=> NWHQUZRrW0GQR1XS
IGR-1 NUPlZVRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDXSpBKSzVyPUKuOlIxOzVizszN NV;QOG5FW0GQR1XS
GOTO M2DpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPCTWM2OD1{Lk[1N|c4KM7:TR?= MYPTRW5ITVJ?
NCI-H1650 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fyWWlEPTB;Mj63NlIyPSEQvF2= MkLHV2FPT0WU
NCI-H1581 M{PBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjPZWhqUUN3ME2yMlc6PjhzIN88US=> Moj6V2FPT0WU
NCI-H2405 NUH4VW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr1[ndNUUN3ME2yMlgzPzh{IN88US=> MoPvV2FPT0WU
U-118-MG Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLRTWM2OD1{Lkm2OFkyKM7:TR?= NI\LNXBUSU6JRWK=
DoTc2-4510 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\5cGFKSzVyPUOuNFE1OTdizszN NEHibZJUSU6JRWK=
NCI-H596 NILz[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNwMES5PVch|ryP NInOTG1USU6JRWK=
MPP-89 NXriTVFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\JTWM2OD1|LkC1OlY3KM7:TR?= NVji[41xW0GQR1XS
GCIY NV7YVm1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNwMkC0PVEh|ryP NGjJZ2ZUSU6JRWK=
SW626 M33LW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLLXGdjUUN3ME2zMlI1PTR|IN88US=> M3zWRnNCVkeHUh?=
OCI-AML2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T2SGlEPTB;Mz6zNVI4OiEQvF2= M2DMOXNCVkeHUh?=
NBsusSR NV\ZZ4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hTWM2OD1|LkO0PVM5KM7:TR?= M1:1R3NCVkeHUh?=
AN3-CA NHKyNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17t[GlEPTB;Mz60OFI{QCEQvF2= M2rxNHNCVkeHUh?=
EFM-19 NH7XfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTNwNEizN|kh|ryP MkOxV2FPT0WU
RVH-421 M2LGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLyTWM2OD1|LkW2PFc4KM7:TR?= NXvhOoxNW0GQR1XS
5637 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNwNkGxNFMh|ryP M2LvbXNCVkeHUh?=
PANC-08-13 Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNwNkO0O|Ih|ryP NHf1XZpUSU6JRWK=
H9 M33ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnX[ZJ5UUN3ME2zMlY4OTR2IN88US=> M1K1fHNCVkeHUh?=
KARPAS-299 NIDEPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwNkezOlEh|ryP NVL6d41IW0GQR1XS
TE-5 NV:yZ5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGxTWM2OD1|LkewO|A6KM7:TR?= M4r2W3NCVkeHUh?=
NOS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTNwN{m4N|Qh|ryP M1vlN3NCVkeHUh?=
HH NFzsZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DsT2lEPTB;Mz64N|g3QCEQvF2= MlvkV2FPT0WU
769-P MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvhO|FVUUN3ME2zMlg6PTFizszN M2P4S3NCVkeHUh?=
CHP-212 NYjtR|FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zxemlEPTB;Mz65NlU1QSEQvF2= Mn:4V2FPT0WU
NCI-H82 Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fZfGlEPTB;Mz65OVk{PiEQvF2= NVK5SpZHW0GQR1XS
Mo-T NHX4V3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTRwMESzNVIh|ryP MoDIV2FPT0WU
BB65-RCC Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfCTWM2OD12LkC0N|k6KM7:TR?= MnT1V2FPT0WU
SW1990 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3mfpNvUUN3ME20MlA2QTB6IN88US=> M2TjS3NCVkeHUh?=
LK-2 NUK3enhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvjPG9lUUN3ME20MlEyOjl|IN88US=> Mnj3V2FPT0WU
ES5 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwMUO5PFUh|ryP NXXxPJhlW0GQR1XS
JVM-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnSUmdKSzVyPUSuNVgzOjJizszN NYXYb|FVW0GQR1XS
RPMI-7951 NGLLUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnHTWM2OD12LkKyOFE{KM7:TR?= NX7oc|FZW0GQR1XS
Calu-6 M3X1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW2N5ZKSzVyPUSuNlc5QDFizszN NGO3ZoVUSU6JRWK=
LC-2-ad M1TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP5TWM2OD12LkK5OVY5KM7:TR?= MnrQV2FPT0WU
SW954 NUXYUXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jhOGlEPTB;ND6yPVY3KM7:TR?= NHTCfGxUSU6JRWK=
H-EMC-SS Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXOeZBKSzVyPUSuN|E5OzFizszN NFXydZRUSU6JRWK=
ES3 NHS1NmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwM{W0OFEh|ryP NVPzO2VvW0GQR1XS
no-11 NWL0[I85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7FW3FKSzVyPUSuN|U2PTRizszN NVjOUZdUW0GQR1XS
LAN-6 M{\Ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\Q[GlLUUN3ME20MlQ2OTh7IN88US=> MmLyV2FPT0WU
FTC-133 M1rheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe1W|BOUUN3ME20MlU{QTVizszN MULTRW5ITVJ?
8505C M1rLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXlTWM2OD12LkW0NlMh|ryP NX7ocphRW0GQR1XS
SW620 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW4TWM2OD12LkW3NFU4KM7:TR?= M4jqT3NCVkeHUh?=
BCPAP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXoNldWUUN3ME20MlY{PDhzIN88US=> M1r5dnNCVkeHUh?=
SK-LU-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELkSnBKSzVyPUSuOlYxQDlizszN NUjIclVRW0GQR1XS
NCI-H1623 NWP6dnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRwN{CyNlgh|ryP NV7rNWRkW0GQR1XS
C2BBe1 NVjBN|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfFOHFoUUN3ME20Mlc1ODB6IN88US=> NXjiVnZTW0GQR1XS
GP5d MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLVVJByUUN3ME20Mlc5Ozh6IN88US=> MmnOV2FPT0WU
NB6 M3TyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDTWM2OD12Lki2NlA1KM7:TR?= NXyyW|dtW0GQR1XS
MDA-MB-157 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnUTWM2OD12Lki4O|Yh|ryP M3HqTXNCVkeHUh?=
UMC-11 M32ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwOEi5OlQh|ryP MUfTRW5ITVJ?
HCC1419 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nXR2lEPTB;ND65NFA3OyEQvF2= M1HpeXNCVkeHUh?=
NCI-H2029 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWbXpKSzVyPUSuPVQyQDVizszN M1y3VHNCVkeHUh?=
LXF-289 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nLW2lEPTB;NT6wN|cyQSEQvF2= NXzmbFJWW0GQR1XS
KINGS-1 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fHTmlEPTB;NT6wO|c1PCEQvF2= MoXsV2FPT0WU
HD-MY-Z NXzXWnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\NSmlEPTB;NT6yN|k3QSEQvF2= NIfKSHBUSU6JRWK=
ESS-1 NWDPd246T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X1ZWlEPTB;NT6yOVU6PyEQvF2= M4\nUnNCVkeHUh?=
GI-1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHnSW1KSzVyPUWuNlc6OjZizszN NFLrcpdUSU6JRWK=
RPMI-2650 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HwcWlEPTB;NT6zOlE3KM7:TR?= M{nu[XNCVkeHUh?=
IA-LM MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwM{m4O|Eh|ryP M4XoeHNCVkeHUh?=
KP-4 M1[xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C3TWlEPTB;NT60OlM{PCEQvF2= M4PEVnNCVkeHUh?=
G-402 NVXsblJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTVwNUG4OlUh|ryP MnzDV2FPT0WU
OS-RC-2 NEP5NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVwNUK2NFQh|ryP NXy4d4dRW0GQR1XS
NCI-H1155 NUTne41QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTVwNUS5OVUh|ryP MoPwV2FPT0WU
OE19 NHHaNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonYTWM2OD13Lk[4OlI1KM7:TR?= M{\RWHNCVkeHUh?=
U-2-OS NEPYWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e2dmlEPTB;NT64PVAyOyEQvF2= Mk\1V2FPT0WU
SCC-15 M3;SWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLL[2pKSzVyPUWuPVM3PjJizszN Mk\nV2FPT0WU
NCI-H630 M4\PPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7QTWM2OD13Lkm5OFA1KM7:TR?= MmrUV2FPT0WU
PFSK-1 NW\1e4hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHWWo1zUUN3ME22MlA2OjV7IN88US=> Mo\GV2FPT0WU
NCI-H1770 M{\xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG5eHBKSzVyPU[uNlA5PzRizszN MlLOV2FPT0WU
SK-MEL-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP6co5KSzVyPU[uOFI6OTVizszN NHHXeIpUSU6JRWK=
LB1047-RCC NVXyfHJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vJfGlEPTB;Nj60O|YzPSEQvF2= NIDRPZFUSU6JRWK=
NCI-H446 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHjelZNUUN3ME22MlYzQTJ3IN88US=> Mnq2V2FPT0WU
SW780 NXPZbWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwN{CxPFUh|ryP M17w[nNCVkeHUh?=
NEC8 M2X3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLmTWM2OD14Lke2OlMh|ryP NEfhdG5USU6JRWK=
NOMO-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTZwN{ixNVEh|ryP NV\Zb5FCW0GQR1XS
COLO-668 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZwOESzPFch|ryP NFHkSYdUSU6JRWK=
MC116 M{TF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL2TWM2OD14LkmzPFk4KM7:TR?= MnfsV2FPT0WU
HCC1937 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X5dWlEPTB;Nj65PVI2OSEQvF2= M1jXZXNCVkeHUh?=
NCI-N87 NFnRdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtTWM2OD15LkG5Nlk{KM7:TR?= M3vJR3NCVkeHUh?=
COLO-320-HSR NGrPUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfuc2FKSzVyPUeuNlI4OzhizszN M{GwVnNCVkeHUh?=
HCC1806 NVyzWI05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLoTWM2OD15LkK2NFQ1KM7:TR?= Ml3pV2FPT0WU
OVCAR-3 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7YTWM2OD15LkOzNFM5KM7:TR?= NH7pPGhUSU6JRWK=
NUGC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTdwM{m2PVQh|ryP MXLTRW5ITVJ?
SW1783 M4DGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwNEOxO|Uh|ryP NYPKS5RVW0GQR1XS
GCT MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rJd2lEPTB;Nz61OlkxPiEQvF2= M{C2RXNCVkeHUh?=
NCI-H2126 MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfWTWM2OD15LkezOlI2KM7:TR?= NV3pZ5hrW0GQR1XS
MEL-HO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTdwN{ewOVQh|ryP MnOzV2FPT0WU
CAPAN-1 M32xO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jXW2lEPTB;Nz63O|M2PyEQvF2= MmnGV2FPT0WU
SW756 M3\Lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjITWM2OD15Lke4N|M{KM7:TR?= MnXHV2FPT0WU
SKG-IIIa MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTdwOEG4PVIh|ryP NX\NVY05W0GQR1XS
HCE-T NHvHUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTdwOEe3PFMh|ryP NYDw[29[W0GQR1XS
Ca-Ski MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnLZ2JKSzVyPUeuPVk{QDNizszN NX3OfoY3W0GQR1XS
COLO-684 NXTX[mJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjPSnBKSzVyPUiuNFE5OThizszN M3G0WHNCVkeHUh?=
KYSE-70 NHTOVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3NTWM2OD16LkC3O|I6KM7:TR?= M1vsZ3NCVkeHUh?=
TI-73 M3q2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6zTWM2OD16LkK1PFUyKM7:TR?= NEDy[ItUSU6JRWK=
BT-20 MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfBTWM2OD16LkK2NFUzKM7:TR?= MWPTRW5ITVJ?
MHH-ES-1 NVu5Z5dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HvOWlEPTB;OD61NVg{PCEQvF2= NIfnR29USU6JRWK=
TE-12 NGrWd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJ[4JKSzVyPUiuOVk6OzFizszN NHn5Z|RUSU6JRWK=
YH-13 NXPQN3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRThwNkGwNFgh|ryP NWPPV2V[W0GQR1XS
SF126 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwOEO4OlUh|ryP M{nWenNCVkeHUh?=
J82 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoftTWM2OD16LkmwNFM5KM7:TR?= NH7OUnhUSU6JRWK=
RCC10RGB M3jvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q3bWlEPTB;OD65PVU3OSEQvF2= MXXTRW5ITVJ?
SK-UT-1 NEjrdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjW[mFKSzVyPUmuNFQ6PDVizszN NWDPe2xvW0GQR1XS
LB2241-RCC M4H4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjkcYFKSzVyPUmuNVkyOzdizszN MWnTRW5ITVJ?
LB996-RCC M37wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnBeVJKSzVyPUmuNVk5QSEQvF2= MX7TRW5ITVJ?
EPLC-272H M4XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7OZmw6UUN3ME25MlM4PjV5IN88US=> M37mfHNCVkeHUh?=
CTV-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluyTWM2OD17LkW2OVMzKM7:TR?= MkDPV2FPT0WU
HSC-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL1TWM2OD17LkW3OVUh|ryP MnzXV2FPT0WU
SK-MEL-28 M3P4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\sfGhKSzVyPUmuOlE5QTNizszN M3q3e3NCVkeHUh?=
MMAC-SF NWH4ZnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjVOo1KSzVyPUmuOlg4PSEQvF2= MmTUV2FPT0WU
CP50-MEL-B NWHzNXVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTlwN{W3PFIh|ryP M3vWWnNCVkeHUh?=
HT-1080 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CyWWlEPTB;OT63O|c{QSEQvF2= MknYV2FPT0WU
HEC-1 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFyLkOzOVIh|ryP M2rlXXNCVkeHUh?=
AGS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHndWlKSzVyPUGwMlM4PCEQvF2= Mm\PV2FPT0WU
GAMG MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQWHhKSzVyPUGwMlUyPjJizszN MUDTRW5ITVJ?
SW48 M3XhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFyLkWxPFkh|ryP NHz2T2VUSU6JRWK=
U031 M2XW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLsU4lEUUN3ME2xNE42QTB6IN88US=> NYXyepE4W0GQR1XS
OVCAR-5 M1jLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHxeoJnUUN3ME2xNE43PDJ7IN88US=> NWPZeYNtW0GQR1XS
SF295 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLYSph[UUN3ME2xNE43PzB2IN88US=> M4\5N3NCVkeHUh?=
BHT-101 M1PNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H1TWlEPTB;MUCuO|E4PyEQvF2= MYjTRW5ITVJ?
VMRC-RCZ M4\Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPiTWM2OD1zMT6zNlAyKM7:TR?= NXHtSW1vW0GQR1XS
ACHN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6yTWM2OD1zMT60NlEyKM7:TR?= M1\GSHNCVkeHUh?=
NCI-H526 NVv4Xo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELqUpNKSzVyPUGxMlUxPDNizszN NHrhOoNUSU6JRWK=
MN-60 NGq1e45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPadlE3UUN3ME2xNU42OzlizszN MVnTRW5ITVJ?
NCI-H2291 NI\WbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17NPWlEPTB;MUGuOVQ3PiEQvF2= NGDJTVlUSU6JRWK=
SCC-25 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\BfWpZUUN3ME2xNU44PTV4IN88US=> MXLTRW5ITVJ?
SK-MEL-2 NIm3cI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjubJBrUUN3ME2xNU44PjN5IN88US=> NYXyTVdvW0GQR1XS
SN12C MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzye2xKSzVyPUGxMlk{PTVizszN NFjaW29USU6JRWK=
NCI-H69 NYf5RlJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\ZTXlKSzVyPUGyMlQzOzRizszN M2rlV3NCVkeHUh?=
ME-180 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fTUGlEPTB;MUKuO|A2PCEQvF2= MnvHV2FPT0WU
MC-IXC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH3SlRKSzVyPUGyMlc2OThizszN MVnTRW5ITVJ?
NCI-H2347 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLZXnpjUUN3ME2xNk44PjF2IN88US=> M4DSdnNCVkeHUh?=
M059J MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjHR25KSzVyPUGyMlc4OjdizszN MYTTRW5ITVJ?
A2058 NGrJ[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DveWlEPTB;MUKuPFY5OSEQvF2= M4jHdHNCVkeHUh?=
VA-ES-BJ NH3B[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfZS2VKSzVyPUGyMlg4QDVizszN Ml;FV2FPT0WU
Ca9-22 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlntTWM2OD1zMj65OFUyKM7:TR?= NInneolUSU6JRWK=
KNS-42 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGxNmFMUUN3ME2xNk46QTh2IN88US=> MUPTRW5ITVJ?
LoVo NFnMNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W3c2lEPTB;MUOuNlMyOyEQvF2= NFPBcpBUSU6JRWK=
AM-38 M2XEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfxcXhKSzVyPUGzMlI2PjZizszN NUjaNIFvW0GQR1XS
NB5 M3vqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTLTWM2OD1zMz6zO|UzKM7:TR?= MXTTRW5ITVJ?
L-363 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF|LkSwN|Mh|ryP MXrTRW5ITVJ?
SK-MEL-30 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln6TWM2OD1zND6wOlQ2KM7:TR?= M1jLdHNCVkeHUh?=
NCI-H1563 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTsNGx1UUN3ME2xOE43ODN7IN88US=> Mn7KV2FPT0WU
NCI-H2228 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm5TWM2OD1zND62NFc4KM7:TR?= MojoV2FPT0WU
MFM-223 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPLT|VSUUN3ME2xOU4yQDF|IN88US=> MVrTRW5ITVJ?
LB831-BLC NX\wb4FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHpW|V4UUN3ME2xOU4zPzZ5IN88US=> NYflZZdtW0GQR1XS
SW872 M{\PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3OOWdKSzVyPUG1MlMxQDZizszN NEH4fodUSU6JRWK=
NCI-H522 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH75c5JKSzVyPUG1MlM{ODZizszN NYXOXo1jW0GQR1XS
EW-1 M3i1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[zTWM2OD1zNT61OFYzKM7:TR?= NV34fGdPW0GQR1XS
HN NEGyZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1zNT61PVQzKM7:TR?= MYrTRW5ITVJ?
SW837 M2PaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTt[JJTUUN3ME2xOU44QDR5IN88US=> NIX3UoRUSU6JRWK=
SCC-9 M1fTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF3LkixNVQh|ryP NVe5eFVFW0GQR1XS
MKN7 M1;wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW3S|RKSzVyPUG1Mlk4OzJizszN M{m1cHNCVkeHUh?=
KYSE-410 NInobW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HUZmlEPTB;MU[uOVkyKM7:TR?= NIXQOXZUSU6JRWK=
SK-N-DZ M2j3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXlNWczUUN3ME2xOk43OTF4IN88US=> NX;TS|RyW0GQR1XS
COR-L105 NWe1UGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roZWlEPTB;MU[uOlUzQCEQvF2= M3nYbHNCVkeHUh?=
LB2518-MEL NV\VdWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j4[GlEPTB;MU[uPFM5QSEQvF2= NWq2OFVoW0GQR1XS
OVCAR-4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF4Lki4OlIh|ryP MknDV2FPT0WU
TK10 NFPMOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XrbWlEPTB;MU[uPVQ4OyEQvF2= MVHTRW5ITVJ?
KNS-62 M2HON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fOUGlEPTB;MU[uPVc4PyEQvF2= NH:1b3RUSU6JRWK=
RPMI-8866 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u3S2lEPTB;MUeuNVc{OiEQvF2= MVPTRW5ITVJ?
HuP-T4 NHHZVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5LkK0PVUh|ryP MYnTRW5ITVJ?
CGTH-W-1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF5LkWyNVkh|ryP MVLTRW5ITVJ?
T-24 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[xTWM2OD1zNz61N|Q4KM7:TR?= NF;0UI9USU6JRWK=
HT-3 NHHvfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPvcldpUUN3ME2xO{42QTF2IN88US=> MlLjV2FPT0WU
KS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF5Lk[3N{DPxE1? NIPJcYtUSU6JRWK=
NCI-H1792 NX7we5E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHThNnlKSzVyPUG3Mlc6QCEQvF2= MlXyV2FPT0WU
ABC-1 NEL5PY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Z[|JKSzVyPUG3MlgyPDFizszN MX\TRW5ITVJ?
BPH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M164PGlEPTB;MUiuNVY5PSEQvF2= NGjzeo1USU6JRWK=
A431 M3L2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD1zOD60NVI4KM7:TR?= MUXTRW5ITVJ?
T98G MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3VXFrUUN3ME2xPE42OTV5IN88US=> MUPTRW5ITVJ?
BHY NXrpeo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPdmlEPTB;MUiuPFY6KM7:TR?= MV7TRW5ITVJ?
Capan-2 NUfMc5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD2TWM2OD1zOD65NFc5KM7:TR?= M4OwXXNCVkeHUh?=
MDA-MB-175-VII M1P2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF6LkmyNFkh|ryP Mmq4V2FPT0WU
CAL-27 M2TleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DvTmlEPTB;MUmuNFQ5PyEQvF2= M4rpeXNCVkeHUh?=
AsPC-1 M4DrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnRVXdKSzVyPUG5Mlg3PTdizszN NX;D[YtVW0GQR1XS
KU812 NET2VnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxVWlEPTB;MUmuPVU4OyEQvF2= MnPMV2FPT0WU
NCI-H441 NH;1WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X4[2lEPTB;MkCuNFAyKM7:TR?= NWPmdVY3W0GQR1XS
Mewo MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLkV4FKSzVyPUKwMlEzQDhizszN MljrV2FPT0WU
SK-MEL-24 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJyLkG0O|ch|ryP MVvTRW5ITVJ?
NCI-H727 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7PPW01UUN3ME2yNE4zPzB2IN88US=> NVvQXZZyW0GQR1XS
EKVX NVLPenpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzPIhuUUN3ME2yNE43ODZizszN MWPTRW5ITVJ?
RT-112 NVLvXJpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PWcWlEPTB;MkCuOlEzOiEQvF2= NVPT[HU6W0GQR1XS
CAMA-1 NUTyTZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\BTlhKSzVyPUKwMlk5ODNizszN M4LFSHNCVkeHUh?=
SW900 NEnGXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fJSmlEPTB;MkGuNFE1QSEQvF2= M3nNSHNCVkeHUh?=
NCI-H23 NHXsdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCxTWM2OD1{MT6xNlc4KM7:TR?= MXfTRW5ITVJ?
SK-PN-DW NHP5NXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z4fWlEPTB;MkGuNVY1QSEQvF2= NGPhSoZUSU6JRWK=
BB30-HNC NIDTdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJzLkK3OFUh|ryP NYDtPW1{W0GQR1XS
VM-CUB-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;tUlI6UUN3ME2yNU4{PTN4IN88US=> M4SweHNCVkeHUh?=
IST-MEL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD1{MT6zOlkzKM7:TR?= MmDBV2FPT0WU
CTB-1 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\IZmtKSzVyPUKxMlQ4PTVizszN M4nPTnNCVkeHUh?=
LCLC-103H NVnmPJV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLsfXN1UUN3ME2yNk4yPTh{IN88US=> NVHqb4plW0GQR1XS
PANC-03-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ{LkWxOlkh|ryP MWHTRW5ITVJ?
HTC-C3 NYmw[Ic2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJ{LkW1OVUh|ryP M1jLRnNCVkeHUh?=
TE-8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Gxc2lEPTB;MkOuNlU3PSEQvF2= M{X3VnNCVkeHUh?=
NCI-H292 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvCTWM2OD1{NT6zOVM3KM7:TR?= NVvqR5JGW0GQR1XS
COLO-680N NEfueI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPLTWM2OD1{NT62N|I6KM7:TR?= MXTTRW5ITVJ?
KYSE-520 NGr5bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnzRop4UUN3ME2yOU43PDRizszN NGfXd21USU6JRWK=
NB10 NUTIWnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjKWGJ4UUN3ME2yOk4{OTF5IN88US=> MVLTRW5ITVJ?
NCI-H661 NWLzPGFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHBTWM2OD1{Nj60O|E{KM7:TR?= NVTnWXRkW0GQR1XS
GMS-10 NH3mRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ4Lki2N|gh|ryP NHWzWHNUSU6JRWK=
NCI-H2122 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknqTWM2OD1{Nj65PVk5KM7:TR?= Mk\2V2FPT0WU
OVCAR-8 M4fNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTyTWM2OD1{Nz6wOlM5KM7:TR?= NXjsbnZRW0GQR1XS
DJM-1 M1\j[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ5LkG0OVQh|ryP NGf2fWNUSU6JRWK=
UACC-893 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PVemlEPTB;MkeuPVg4QCEQvF2= M{j4WnNCVkeHUh?=
C8166 NFXMb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\nSGx3UUN3ME2yPE43QTN6IN88US=> M2f0PHNCVkeHUh?=
NCI-H1693 M2OxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJ6Lk[5O|Uh|ryP MoDHV2FPT0WU
TYK-nu NFXhU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDOTWM2OD1|MD6wN|Q2KM7:TR?= MY\TRW5ITVJ?
SW1710 M2HPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f2d2lEPTB;M{CuNVI3KM7:TR?= M{LNSnNCVkeHUh?=
A375 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLBTWM2OD1|MD6zNlQ{KM7:TR?= MYHTRW5ITVJ?
HMV-II NWLxRpU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy1PHRtUUN3ME2zNU4{PTl{IN88US=> M{\afXNCVkeHUh?=
NCI-H2087 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGwTYVIUUN3ME2zNU43OzV{IN88US=> NHm3VpNUSU6JRWK=
CAL-54 M2fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTNzLkeyOFEh|ryP NEXveVhUSU6JRWK=
HCC70 NU\DPVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLNNIhKSzVyPUOyMlE{QDdizszN MofUV2FPT0WU
ES1 M4fUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0UXhkUUN3ME2zNk4{ODZ{IN88US=> Mo[4V2FPT0WU
NCI-H1355 M2nWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT6TWM2OD1|Mz6yNFQh|ryP NWHKfWN1W0GQR1XS
CFPAC-1 M2HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTN|LkKzN|Ih|ryP NHfvPHhUSU6JRWK=
MKN28 M{nabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz3dm1nUUN3ME2zN{4{QDB7IN88US=> M2DrV3NCVkeHUh?=
HDLM-2 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN|Lk[5N|Eh|ryP M{O1SXNCVkeHUh?=
PANC-10-05 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrIcIoyUUN3ME2zOE4yODF2IN88US=> M2rFc3NCVkeHUh?=
SAS NHzHOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvrW3FSUUN3ME2zOE41PTZ3IN88US=> NWXJeGxbW0GQR1XS
HCC1395 M3fxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX4XI5UUUN3ME2zOE44OTh4IN88US=> NYjiSox{W0GQR1XS
8305C NYThTW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvlRZBKSzVyPUO1Mlg1OTVizszN M1TwUHNCVkeHUh?=
KM12 NETHPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN4Lke1OFch|ryP MV3TRW5ITVJ?
SW1116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN5LkW5PVIh|ryP M4DpdnNCVkeHUh?=
SK-MEL-1 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml60TWM2OD1|OD6zN|g6KM7:TR?= NWnqTFhPW0GQR1XS
HCC2218 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7uRZMxUUN3ME2zPE43PTF7IN88US=> MYjTRW5ITVJ?
T84 NIHPZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNPFZXUUN3ME2zPE44PDB7IN88US=> MmLhV2FPT0WU
ETK-1 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN7LkCyNkDPxE1? MYrTRW5ITVJ?
COLO-800 NYfJNJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTN7LkO4Olgh|ryP NYGwSGdyW0GQR1XS
CAL-12T NVu5eW1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;rOmtKSzVyPUO5MlUzQDFizszN MVLTRW5ITVJ?
ACN MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRyLkS5NVEh|ryP Mn32V2FPT0WU
SJSA-1 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G4e2lEPTB;NEGuNVU6PiEQvF2= NFjZd4ZUSU6JRWK=
PSN1 NGi0[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHS0cGdKSzVyPUSxMlE4PDlizszN NVm4PYhbW0GQR1XS
D-566MG Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jjOGlEPTB;NEGuNlA5PiEQvF2= MkjaV2FPT0WU
EGI-1 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQT4pKSzVyPUSyMlQzQCEQvF2= MUXTRW5ITVJ?
A204 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC4TWM2OD12Mj62N|g5KM7:TR?= M1PhNXNCVkeHUh?=
Saos-2 NWHic4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR{LkizOlkh|ryP NEOxcIFUSU6JRWK=
SNU-C2B M1XGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoizTWM2OD12Mz62PFc5KM7:TR?= NFzzeGxUSU6JRWK=
HLE NFTpSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR2LkC4OVYh|ryP NYW1XWtmW0GQR1XS
SW1463 M{nhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXiZ3NEUUN3ME20OE46QTdzIN88US=> MYPTRW5ITVJ?
DSH1 NVv5TXRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDL[IZKSzVyPUS1MlAxOzNizszN Ml23V2FPT0WU
MCF7 NHr3WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vzVWlEPTB;NEWuOVA2OSEQvF2= NGXjS3dUSU6JRWK=
K5 NIXkUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW2OJNKSzVyPUS1Mlk1ODVizszN NGSzenJUSU6JRWK=
NCI-H358 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HjSWlEPTB;NEeuNlE2KM7:TR?= M3LGb3NCVkeHUh?=
NCI-H2030 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLzTWM2OD12Nz6yN|c1KM7:TR?= NEmzdIRUSU6JRWK=
SW948 NWf5ZoVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLiXZhKSzVyPUS3MlQ3PCEQvF2= MVnTRW5ITVJ?
BALL-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlNYZKSzVyPUS3MlYyPjhizszN NHrpUphUSU6JRWK=
TE-9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn3blhKSzVyPUS3Mlk2QDFizszN MkTRV2FPT0WU
SK-N-FI M1zLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnxTWM2OD12OD6wN|U5KM7:TR?= NFWxU5RUSU6JRWK=
KALS-1 M3myNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPxcFJKSzVyPUS4MlEzQDlizszN NYfUc5pxW0GQR1XS
HO-1-N-1 NYP3TFFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR6Lke0OFUh|ryP NFnsc2JUSU6JRWK=
NCI-H2452 NWnwOZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXISXZKSzVyPUS5MlEyPTJizszN MWHTRW5ITVJ?
OC-314 NY\q[FFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrrTWM2OD12OT62PFM1KM7:TR?= NEPrUYlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Related Antibodies

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID